AC
ACLS.US Axcelis Technologies Inc
- Market cap
- USD 3.34B
- P/E
- 32.2x
- P/B
- 3.08x
- ROE
- 8.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACLS.US undervalued?
Graham numberACLS.US trades 109.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Axcelis Technologies Inc fundamental analysis
No fundamental analysis for Axcelis Technologies Inc yet.
Axcelis Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Axcelis Technologies Inc
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company provides high energy, high current, and medium current implanters for various application requirements. It also offers aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer tra…
Full company profileAxcelis Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Axcelis Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 267M | 411M | 443M | 343M | 475M | 662M | 920M | 1.13B | 1.02B | 839M | 869M |
| Gross Profit | 99.6M | 150M | 180M | 144M | 199M | 286M | 402M | 491M | 455M | 377M | 359M |
| Operating Income | 16.6M | 47.8M | 60.0M | 24.2M | 58.0M | 127M | 212M | 266M | 211M | 119M | 74.1M |
| EBITDA | 20.4M | 54.0M | 65.6M | 34.0M | 71.0M | 136M | 222M | 297M | 252M | 161M | 120M |
| Net Income | 11.0M | 127M | 45.9M | 17.0M | 50.0M | 98.7M | 183M | 246M | 201M | 120M | 93.7M |
| EPS | 0.36 | 3.80 | 1.35 | 0.50 | 1.46 | 2.88 | 5.46 | 7.43 | 6.15 | 3.80 | 3.01 |
| Balance Sheet | |||||||||||
| Total Assets | 302M | 488M | 548M | 548M | 625M | 753M | 1.01B | 1.28B | 1.35B | 1.36B | 1.48B |
| Total Liabilities | 101M | 135M | 140M | 129M | 143M | 214M | 346M | 417M | 336M | 327M | 364M |
| Shareholders' Equity | 201M | 354M | 408M | 419M | 482M | 539M | 667M | 865M | 1.01B | 1.03B | 1.11B |
| Cash & Short-term Investments | 70.8M | 133M | 178M | 140M | 203M | 295M | 432M | 506M | 571M | 374M | 472M |
| Total Debt | 51.0M | 68.3M | 48.2M | 48.5M | 48.1M | 47.4M | 46.4M | 45.2M | 43.7M | 42.3M | 41.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.80M | 56.3M | 47.0M | -13.6M | 69.7M | 150M | 216M | 157M | 141M | 118M | 102M |
| Capital Expenditure | 2.51M | 7.29M | 4.72M | 12.0M | 7.43M | 8.72M | 10.7M | 20.7M | 12.2M | 11.3M | 10.5M |
| Free Cash Flow | -11.3M | 49.0M | 42.3M | -25.6M | 62.3M | 141M | 205M | 136M | 129M | 107M | 91.8M |
| Ratios | |||||||||||
| ROE | 5.5% | 35.9% | 11.2% | 4.1% | 10.4% | 18.3% | 27.4% | 28.5% | 19.8% | 11.6% | 8.4% |
| ROA | 3.6% | 26.0% | 8.4% | 3.1% | 8.0% | 13.1% | 18.1% | 19.2% | 14.9% | 8.8% | 6.3% |
| Net Profit Margin | 4.1% | 30.9% | 10.4% | 5.0% | 10.5% | 14.9% | 19.9% | 21.8% | 19.7% | 14.3% | 10.8% |
| Debt to Equity | 0.25x | 0.19x | 0.12x | 0.12x | 0.10x | 0.09x | 0.07x | 0.05x | 0.04x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Axcelis Technologies Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.00 | 0.00 | 0.0% |
| 2022 | - | - | - |
| 2021 | USD 4.87M | 0.14 | 4.9% |
| 2020 | USD 9.43M | 0.28 | 18.9% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Jul 1, 2016.
Who owns Axcelis Technologies Inc
- Insiders 0.68%
- Institutions 99.32%
- Public & others 0.00%
- Shares outstanding 30.9M
- Free float 30.7M
Top funds holding ACLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.86M | 6.01% | -0.08% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 982K | 3.18% | +0.33% | Sep 2026 |
| Amundi Fds Global Equity A EUR C | 967K | 3.13% | +1.26% | Sep 2026 |
| iShares Russell 2000 ETF | 799K | 2.59% | 0.00% | Oct 2026 |
| Vanguard Information Technology ETF | 745K | 2.41% | +0.23% | Sep 2026 |
| Vanguard Small Cap Index | 695K | 2.25% | -1.60% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 563K | 1.82% | -2.84% | Sep 2026 |
| Fidelity Contrafund | 501K | 1.62% | +21.52% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 468K | 1.51% | +15.53% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 452K | 1.46% | +0.74% | Sep 2026 |
| Fidelity Small Cap Index | 344K | 1.11% | +0.15% | Aug 2026 |
| BNP Paribas Disrpt Tech Cl D | 331K | 1.07% | -0.10% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 324K | 1.05% | -8.34% | Aug 2026 |
| Fidelity Small Cap Discovery | 299K | 0.97% | +6.37% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 295K | 0.95% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 281K | 0.91% | -0.05% | Oct 2026 |
| Fidelity Series Small Cap Discovery | 267K | 0.86% | +13.62% | Aug 2026 |
| BNP Paribas US Small Cap ClassicC | 262K | 0.85% | -0.76% | Sep 2026 |
| Fidelity Series Small Cap Opps | 212K | 0.69% | -12.16% | Aug 2026 |
| American Century Small Cap Value Inv | 210K | 0.68% | +31.25% | Sep 2026 |
Top institutions holding ACLS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.03M | 16.29% | +1.88% | Jun 2026 |
| FMR Inc | 4.13M | 13.36% | +69.71% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.48M | 8.03% | -0.38% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.39M | 4.49% | +0.27% | Jun 2026 |
| State Street Corp | 1.23M | 3.99% | +3.54% | Jun 2026 |
| Victory Capital Management Inc. | 1.13M | 3.67% | -11.34% | Jun 2026 |
| Reinhart Mahoney Capital Management Inc | 1.06M | 3.43% | +14.21% | Sep 2026 |
| Geode Capital Management, LLC | 834K | 2.70% | +2.75% | Jun 2026 |
| BNP Paribas Investment Partners SA | 803K | 2.60% | -20.17% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 791K | 2.56% | +11.52% | Sep 2026 |
| Balyasny Asset Management LLC | 616K | 2.00% | -54.84% | Jun 2026 |
| PRIMECAP Management Company | 610K | 1.98% | -7.32% | Jun 2026 |
| Amvescap Plc. | 528K | 1.71% | +219.69% | Jun 2026 |
| Charles Schwab Investment Management Inc | 416K | 1.35% | -6.63% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 394K | 1.28% | +8.90% | Jun 2026 |
| Barrow Hanley Mewhinney & Strauss LLC | 392K | 1.27% | +688,040.35% | Jun 2026 |
| Manufacturers Life Insurance Co | 384K | 1.24% | -21.96% | Jun 2026 |
| Northern Trust Corp | 382K | 1.24% | -8.32% | Jun 2026 |
| American Century Companies Inc | 370K | 1.20% | -61.14% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 366K | 1.19% | -37.06% | Jun 2026 |
Axcelis Technologies Inc company profile
- Company name
- Axcelis Technologies Inc
- Ticker
- ACLS.US
- Exchange
- USA Stocks
- Listed since
- Jul 11, 2000
- Sector
- Technology
- Industry
- Semiconductors & Semiconductor Equipment
- Employees
- 1,465
- Fiscal year end
- December
- Address
- 108 Cherry Hill Drive, Beverly, MA, United States, 01915-1088
- Phone
- 978 787 4000
- Website
- axcelis.com
About Axcelis Technologies Inc
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company provides high energy, high current, and medium current implanters for various application requirements. It also offers aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company sells its equipment and services to semiconductor chip manufacturers through its direct sales force. Axcelis Technologies, Inc. was founded in 1978 and is headquartered in Beverly, Massachusetts.
Axcelis Technologies Inc management
5- Dr. Russell J. Low Ph.D.CEO, President & Director · born 1971
- Mr. Gregory F. Redinbo Ph.D.Chief Strategy Officer & Executive VP of Strategic Marketing & Technology · born 1965
- Ms. Eileen J. Evans Esq.Executive VP of Human Resources and Legal, General Counsel & Secretary · born 1968
- Mr. Gerald M. BlumenstockExecutive VP & GM of Implant Business Unit (IBU) · born 1969
- Dr. Christopher J. Tatnall Ph.D.Executive Vice President of Global Customer Operations · born 1973